Search research articles
Contact Us
Filters
Showing results (281-290 of 336) with videos related to
Page
of 34
Sort By:
BMC Genomics
|
February 26, 2014
A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer
Debmalya Barh, Neha Jain, Sandeep Tiwari, et al.
Current Psychopharmacology
|
October 28, 2021
Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) During Adolescent Brain Development
Kenneth Blum, Abdalla Bowirrat, Marjorie C Gondre Lewis, et al.
Molecular Neurobiology
|
May 25, 2019
Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization
Kenneth Blum, M C Gondré-Lewis, E J Modestino, et al.
Current Neuropharmacology
|
June 2, 2011
Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Abdalla Bowirrat, Thomas J H Chen, Kenneth Blum, et al.
Journal of Personalized Medicine
|
December 24, 2025
Pharmacoepigenomics in Personalized Medicine: A Hypothesis-Generating Approach to Introduce CpG-PGx SNPs as New Candidates for a Systematic Insight into Genomic-Epigenomic-Phenomic-Pharmacogenomics (G-E-Ph-PGx) Axis
Alireza Sharafshah, Kenneth Blum, Kai-Uwe Lewandrowski, et al.
Molecular Neurobiology
|
September 28, 2011
Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?
Kenneth Blum, Thomas J H Chen, John Bailey, et al.
Journal of Personalized Medicine
|
December 23, 2022
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
Mauro Ceccanti, Kenneth Blum, Abdalla Bowirrat, et al.
European Journal of Pain (London, England)
|
May 6, 2026
Sustained Attention Instability as a Cognitive Biomarker in Chronic Spine Pain: A 90-second Visual Attention Test
Kai-Uwe Lewandrowski, Kenneth Blum, Morgan Lorio, et al.
Journal of Psychoactive Drugs
|
August 24, 2011
Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map
Thomas J H Chen, Kenneth Blum, Amanda L C Chen, et al.
Journal of Personalized Medicine
|
September 23, 2022
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control Subjects
Kenneth Blum, David Han, Ashim Gupta, et al.
Page
of 34
Search research articles
Search
Showing results (281-290 of 336) with videos related to
Sort By:
Page
of 34
BMC Genomics
|
February 26, 2014
A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer
Debmalya Barh, Neha Jain, Sandeep Tiwari, et al.
Current Psychopharmacology
|
October 28, 2021
Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) During Adolescent Brain Development
Kenneth Blum, Abdalla Bowirrat, Marjorie C Gondre Lewis, et al.
Molecular Neurobiology
|
May 25, 2019
Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization
Kenneth Blum, M C Gondré-Lewis, E J Modestino, et al.
Current Neuropharmacology
|
June 2, 2011
Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Abdalla Bowirrat, Thomas J H Chen, Kenneth Blum, et al.
Journal of Personalized Medicine
|
December 24, 2025
Pharmacoepigenomics in Personalized Medicine: A Hypothesis-Generating Approach to Introduce CpG-PGx SNPs as New Candidates for a Systematic Insight into Genomic-Epigenomic-Phenomic-Pharmacogenomics (G-E-Ph-PGx) Axis
Alireza Sharafshah, Kenneth Blum, Kai-Uwe Lewandrowski, et al.
Molecular Neurobiology
|
September 28, 2011
Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?
Kenneth Blum, Thomas J H Chen, John Bailey, et al.
Journal of Personalized Medicine
|
December 23, 2022
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
Mauro Ceccanti, Kenneth Blum, Abdalla Bowirrat, et al.
European Journal of Pain (London, England)
|
May 6, 2026
Sustained Attention Instability as a Cognitive Biomarker in Chronic Spine Pain: A 90-second Visual Attention Test
Kai-Uwe Lewandrowski, Kenneth Blum, Morgan Lorio, et al.
Journal of Psychoactive Drugs
|
August 24, 2011
Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map
Thomas J H Chen, Kenneth Blum, Amanda L C Chen, et al.
Journal of Personalized Medicine
|
September 23, 2022
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control Subjects
Kenneth Blum, David Han, Ashim Gupta, et al.
Page
of 34